Annexon is pioneering the development of classical complement pathway inhibitors for the treatment of neurodegenerative and autoimmune diseases. While the role of the pathway in autoimmunity has been known for some time, the Company's breakthrough research has unveiled that the pathway is activated as the aging brain encounters stress or disease to contribute to loss of nerve connections in neurodegeneration. Annexon strives to rapidly bring what may be disease-modifying therapies to patients suffering from these diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/15/14 | $34,000,000 | Series A-1 |
Novartis Venture Funds | undisclosed |
